Vanguard Group Inc. Cuts Stake in ADMA Biologics Inc $ADMA

Vanguard Group Inc. lowered its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 0.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 20,854,669 shares of the biotechnology company’s stock after selling 120,327 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of ADMA Biologics worth $380,389,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Rothschild Investment LLC boosted its position in shares of ADMA Biologics by 373.8% during the 3rd quarter. Rothschild Investment LLC now owns 1,895 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,495 shares in the last quarter. Optima Capital LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter valued at approximately $36,000. Clearstead Advisors LLC lifted its position in shares of ADMA Biologics by 55.7% during the 3rd quarter. Clearstead Advisors LLC now owns 2,222 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 795 shares during the period. iSAM Funds UK Ltd acquired a new stake in shares of ADMA Biologics during the 3rd quarter valued at approximately $34,000. Finally, RiverPark Advisors LLC acquired a new stake in shares of ADMA Biologics during the 3rd quarter valued at approximately $35,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Down 1.7%

ADMA opened at $10.08 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 6.71 and a quick ratio of 3.74. The stock has a market capitalization of $2.40 billion, a price-to-earnings ratio of 16.80 and a beta of 0.83. The business has a 50-day moving average of $12.26 and a two-hundred day moving average of $15.51. ADMA Biologics Inc has a 12 month low of $7.21 and a 12 month high of $23.98.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting the consensus estimate of $0.19. The company had revenue of $114.49 million during the quarter, compared to analysts’ expectations of $139.98 million. ADMA Biologics had a return on equity of 37.52% and a net margin of 28.80%.The firm’s revenue was down .3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.11 EPS. On average, research analysts expect that ADMA Biologics Inc will post 0.93 earnings per share for the current year.

Insider Activity

In other ADMA Biologics news, COO Kaitlin M. Kestenberg-Messina sold 10,096 shares of ADMA Biologics stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $15.63, for a total value of $157,800.48. Following the completion of the sale, the chief operating officer owned 466,600 shares in the company, valued at $7,292,958. The trade was a 2.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Steve Elms purchased 7,000 shares of the stock in a transaction on Thursday, March 5th. The stock was acquired at an average price of $15.67 per share, with a total value of $109,690.00. Following the acquisition, the director directly owned 2,038,730 shares in the company, valued at $31,946,899.10. This trade represents a 0.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 3.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research report on Thursday, March 26th. Wall Street Zen cut shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research note on Monday. Zacks Research cut shares of ADMA Biologics from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 27th. Canaccord Genuity Group initiated coverage on shares of ADMA Biologics in a research note on Monday, April 20th. They issued a “buy” rating and a $21.00 price objective on the stock. Finally, Mizuho lowered their price objective on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, ADMA Biologics currently has a consensus rating of “Moderate Buy” and a consensus target price of $24.33.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: FDA expands ASCENIV label to include younger pediatric patients, widening the addressable market for ADMA’s growth product and supporting longer-term demand for ASCENIV. FDA approves Asceniv for children with primary humoral immunodeficiency
• Positive Sentiment: Q1 showed strong profitability and cash generation: adjusted net income and adjusted EBITDA grew year-over-year and the company reported $58M cash from operations, demonstrating financial flexibility even as top-line growth is mixed. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Neutral Sentiment: Earnings call transcript provides management commentary reiterating confidence in ASCENIV demand but also explains the decision to withdraw long?term guidance amid evolving plasma/IG market dynamics — useful context for modeling but not a clear near-term catalyst. ADMA Biologics, Inc. (ADMA) Q1 2026 Earnings Call Transcript
• Negative Sentiment: Revenue missed expectations — Q1 revenue of $114.5M vs. analyst estimates near $140M — even though EPS met consensus. The top-line shortfall weighs on near-term valuation and growth assumptions. Listen to Conference Call / MarketBeat summary
• Negative Sentiment: ADMA cut its FY?2026 revenue outlook to $530M–$560M (vs. consensus ? $625M) and withdrew long?term guidance, signaling more conservative near-term expectations for the plasma/IG market — a primary driver of the share decline. ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
• Negative Sentiment: Multiple law firms have launched securities?fraud investigations and encouraged shareholders to contact them after the sudden share drop, introducing legal risk and potential distraction for management. BREAKING: ADMA Biologics Shares Fall Over 24%; Investors Encouraged to Contact Block & Leviton to Possibly Recover Losses ADMA Investor News: Rosen Law Firm investigation BFA Law investigation notice

ADMA Biologics Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.